Descemet’s stripping only shows promise in some Fuchs’ patients

PARIS — For some patients, the use of a topical Rho kinase inhibitor following a Descemet’s stripping only procedure for Fuchs’ dystrophy “can be life-changing,” Kathryn Colby, MD, PhD, said at EuCornea 2019.

Colby, who is chair of the department of ophthalmology and visual sciences at the University of Chicago, has been interested in this line of research since 2013, even though the idea was not well received in the cornea community at the time, she said.